{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"19"},{"groupId":"OG002","value":"15"}]}],"title":"TSH > ULN"},{"categories":[{"measurements":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"13"},{"groupId":"OG002","value":"9"}]}],"title":"TSH > ULN WITH TSH <= ULN AT BASELINE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"1"}]}],"title":"TSH > ULN WITH AT LEAST ONE FT3/FT4 TEST VALUE < LLN"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"}]}],"title":"TSH > ULN WITH ALL OTHER FT3/FT4 TEST VALUES >= LLN"},{"categories":[{"measurements":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"13"}]}],"title":"TSH > ULN WITH FT3/FT4 TEST MISSING"},{"categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"6"}]}],"title":"TSH < LLN"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"4"}]}],"title":"TSH < LLN WITH TSH >= LLN AT BASELINE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"}]}],"title":"TSH < LLN WITH AT LEAST ONE FT3/FT4 TEST VALUE > ULN"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}],"title":"TSH < LLN WITH ALL OTHER FT3/FT4 TEST VALUES <= ULN"},{"categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"5"}]}],"title":"TSH < LLN WITH FT3/FT4 TEST MISSING"}],"denoms":[{"counts":[{"groupId":"OG000","value":"83"},{"groupId":"OG001","value":"47"},{"groupId":"OG002","value":"72"}],"units":"Participants"}],"groups":[{"description":"3mg/kg of nivolumab","id":"OG000","title":"Nivolumab Monotherapy (Expansion)"},{"description":"3 mg/kg of nivolumab and\n\n1 mg/kg of ipilimumab Q3W for 4 doses, followed by nivolumab alone at 3 mg/kg Q2W","id":"OG001","title":"Nivolumab + Ipilimumab"},{"description":"3 mg/kg of nivolumab Q2W + 3 mg/kg of lirilumab Q4W","id":"OG002","title":"Nivolumab + Lirilumab"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All Treated Participants","reportingStatus":"POSTED","timeFrame":"Nivo Mono: approximately up to 6 years and 9 months Nivo Ipi: approximately up to 5 months Nivo Liri: approximately up to 4 years 1 month","title":"Number of Participants With Clinical Laboratory Abnormalities by Worst Toxicity Grade - Thyroid","type":"PRIMARY","unitOfMeasure":"Participants"}